To reduce the risk of infection in patients with some tumors, who are receiving strong chemotherapy that may cause severe neutropenia with fever.

To decrease incidence of febrile neutropenia and its sequelae in patients with :

-Non-myeloid malignancies receiving myelosuppressive chemotherapy

-Following induction and consolidation treatment for acute myeloid leukemia

-myeloablative chemotherapy followed by bone marrow transplantation (BMT)

To mobilize autologous peripheral blood progenitor cells for patients undergoing peripheral blood progenitor cell (PBPC) collection.